228 related articles for article (PubMed ID: 17483364)
21. Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB
Cancer Cell; 2018 Dec; 34(6):906-921.e8. PubMed ID: 30537513
[TBL] [Abstract][Full Text] [Related]
22. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
Medh RD; Saeed MF; Johnson BH; Thompson EB
Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line.
Hosono N; Kishi S; Iho S; Urasaki Y; Yoshida A; Kurooka H; Yokota Y; Ueda T
Cancer Sci; 2010 Mar; 101(3):767-73. PubMed ID: 20067466
[TBL] [Abstract][Full Text] [Related]
24. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance.
Catts VS; Farnsworth ML; Haber M; Norris MD; Lutze-Mann LH; Lock RB
Leukemia; 2001 Jun; 15(6):929-35. PubMed ID: 11417479
[TBL] [Abstract][Full Text] [Related]
25. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia.
Ploner C; Schmidt S; Presul E; Renner K; Schröcksnadel K; Rainer J; Riml S; Kofler R
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):153-60. PubMed ID: 15860257
[TBL] [Abstract][Full Text] [Related]
27. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Gagné V; Rousseau J; Labuda M; Sharif-Askari B; Brukner I; Laverdière C; Ceppi F; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
Clin Cancer Res; 2013 Sep; 19(18):5240-9. PubMed ID: 23908358
[TBL] [Abstract][Full Text] [Related]
28. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
29. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
Toscan CE; Failes T; Arndt GM; Lock RB
J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
[TBL] [Abstract][Full Text] [Related]
30. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
[TBL] [Abstract][Full Text] [Related]
31. Glucocorticoid-mediated co-regulation of RCAN1-1, E4BP4 and BIM in human leukemia cells susceptible to apoptosis.
Saenz GJ; Hovanessian R; Gisis AD; Medh RD
Biochem Biophys Res Commun; 2015 Aug; 463(4):1291-6. PubMed ID: 26102033
[TBL] [Abstract][Full Text] [Related]
32. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor.
Chen W; Rogatsky I; Garabedian MJ
Mol Endocrinol; 2006 Mar; 20(3):560-72. PubMed ID: 16239257
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia.
Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
Leukemia; 2004 Mar; 18(3):530-7. PubMed ID: 14724649
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
35. Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children.
Koga Y; Matsuzaki A; Suminoe A; Hattori H; Kanemitsu S; Hara T
Pediatr Blood Cancer; 2005 Aug; 45(2):121-7. PubMed ID: 15704223
[TBL] [Abstract][Full Text] [Related]
36. Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally.
Brown JA; Ferrando A
Cancer Cell; 2018 Dec; 34(6):869-871. PubMed ID: 30537507
[TBL] [Abstract][Full Text] [Related]
37. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members.
Laane E; Panaretakis T; Pokrovskaja K; Buentke E; Corcoran M; Söderhäll S; Heyman M; Mazur J; Zhivotovsky B; Porwit A; Grandér D
Haematologica; 2007 Nov; 92(11):1460-9. PubMed ID: 18024393
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.
Grausenburger R; Bastelberger S; Eckert C; Kauer M; Stanulla M; Frech C; Bauer E; Stoiber D; von Stackelberg A; Attarbaschi A; Haas OA; Panzer-Grümayer R
Leuk Lymphoma; 2016 May; 57(5):1163-73. PubMed ID: 26327566
[TBL] [Abstract][Full Text] [Related]
39. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.
van Galen JC; Kuiper RP; van Emst L; Levers M; Tijchon E; Scheijen B; Waanders E; van Reijmersdal SV; Gilissen C; van Kessel AG; Hoogerbrugge PM; van Leeuwen FN
Blood; 2010 Jun; 115(23):4810-9. PubMed ID: 20354172
[TBL] [Abstract][Full Text] [Related]
40. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
